Two mitochondrial quality-control genes stand out in rheumatoid arthritis blood

When mitochondria are damaged, they leak reactive oxygen species and inflammatory signals — a process increasingly linked to autoimmune disease. In rheumatoid arthritis, dysfunctional mitochondria have been implicated in activating the joint-lining cells that drive destruction, but the specific quality-control genes involved were poorly mapped. A team at The Second Affiliated Hospital of Chengdu Medical College (Xiao, Wu and colleagues) combined two bulk blood transcriptomic datasets (248 rheumatoid arthritis samples, 88 controls) with single-cell RNA sequencing of 11,719 blood cells to find them.

How did CDC42 and RBBP7 survive the filters?

The researchers layered co-expression network analysis and differential-expression analysis, then required candidates to survive three different machine-learning methods (LASSO, support-vector-machine recursive feature elimination, and random forest). Nine mitochondrial quality-control candidates remained; after validation, CDC42 — a small signaling protein involved in cell shape and movement, upregulated in patients — and RBBP7 — part of a chromatin-remodeling complex, downregulated — stood out. Both patterns were confirmed by RT-qPCR in independent samples.

What do the two genes connect to?

CDC42 was linked to JAK-STAT signaling — the pathway targeted by existing rheumatoid arthritis drugs such as tofacitinib — suggesting mitochondrial quality control and established inflammatory signaling may be intertwined rather than separate. Fifteen immune cell subsets differed between patients and controls; monocytes, the white blood cells that flood inflamed joints, correlated positively with CDC42 and negatively with RBBP7, while RBBP7 was relatively highly expressed in antibody-producing B cells, with exploratory hints of B-cell-to-monocyte communication via CCL5-CCR1.

What would it take for this to matter clinically?

Functional proof. The study is observational and based on blood, not joint tissue; mRNA levels do not always track protein activity; and the authors themselves call for perturbation experiments — switching these genes up or down in immune cells and measuring mitochondrial membrane potential, reactive oxygen species, mitophagy and cytokine output — to learn whether CDC42 and RBBP7 drive the disease or merely mark it. Until then they are candidate biomarkers and research targets, not a test or a treatment.

Where the evidence stands

• Established: Mitochondrial dysfunction and failed quality control contribute to inflammatory signaling, and mitochondrial defects have been implicated in rheumatoid arthritis joint cells.
• Preliminary: In bulk (248 patients, 88 controls) and single-cell (11,719 cells) blood data (Scientific Reports, 2026), CDC42 was upregulated and RBBP7 downregulated in rheumatoid arthritis, with monocyte and B-cell signatures and a CDC42 link to JAK-STAT signaling; expression differences were confirmed by RT-qPCR.
• Absent: Evidence from joint tissue, protein-level confirmation, and any functional proof that CDC42 or RBBP7 causes or modifies rheumatoid arthritis — and any diagnostic or treatment based on them.